SCHEMBL1680955

SCHEMBL1680955

Brc1ccccc1Oc1ccccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.56
GRM4 Q14833 1/20 0.47
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
POLB P06746 1/20 0.39
CCR1 P32246 1/20 0.39
CCR5 P51681 1/20 0.39
CCR8 P51685 1/20 0.39
METAP1 P53582 1/20 0.39
BLM P54132 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30811087 1.00 KDM4E (0.56) KDM4EGRM4LMNASMN1; SMN2RAB9A
SCHEMBL11138427 0.85 KDM4E (0.66) KDM4ELMNASMN1; SMN2RAB9ANPC1
SCHEMBL29733596 0.84 KDM4E (0.53) KDM4EGRM4LMNASMN1; SMN2RAB9A
SCHEMBL22807516 0.84 KDM4E (0.53) KDM4EGRM4LMNASMN1; SMN2RAB9A
SCHEMBL9359315 0.83 KDM4E (0.63) KDM4ELMNASMN1; SMN2RAB9ANPC1
SCHEMBL3288850 0.83 KDM4E (0.47) KDM4EGRM4LMNASMN1; SMN2MEN1
SCHEMBL15916364 0.79 LMNA (0.46) KDM4EGRM4LMNASMN1; SMN2RAB9A
SCHEMBL10549193 0.79 KDM4E (0.44) KDM4EGRM4LMNASMN1; SMN2RAB9A
SCHEMBL9722803 0.79 KDM4E (0.44) KDM4EGRM4LMNASMN1; SMN2RAB9A
SCHEMBL16613062 0.78 KDM4E (0.47) KDM4EGRM4LMNASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111527094-B Compound, polymer compound, material for organic element, organic electroluminescent element, display device, and lighting device 学校法人关西学院 2024-03-26 CN disclosed
CN-111527094-A Compound having boron as spiro atom and polymer compound thereof 学校法人关西学院 2020-08-11 CN disclosed
CN-107011251-B Synthesis method and application of 2- (2-chlorophenoxy) pyridine compound 温州医科大学 2020-08-11 CN disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-0288810-B1 HETEROCYCLIC NEOPHANE ANALOGS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PESTICIDES HOECHST AKTIENGESELLSCHAFT (DE) 1992-12-02 EP disclosed
EP-0288810-A1 Heterocyclic neophane analogs, processes for their preparation and their use as pesticides HOECHST AKTIENGESELLSCHAFT (DE) 1988-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 KDM4E 3245/4885GRM4 3693/4885LMNA 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.